Business UpdateJun 17, 2026, 07:06 AM
Can-Fite BioPharma to Seek Partnerships at BIO International Convention
AI Summary
Can-Fite BioPharma Ltd. announced its participation in the BIO International Convention 2026, where it will conduct partnering meetings with pharmaceutical and biotechnology firms. The company aims to discuss licensing and commercialization opportunities for its advanced clinical-stage pipeline, including Namodenoson in pivotal Phase III for HCC and Piclidenoson in pivotal Phase III for psoriasis. Can-Fite's A3 adenosine receptor (A3AR) platform has shown a favorable safety profile, and existing licensing agreements have already generated approximately $20 million in payments.
Key Highlights
- Can-Fite BioPharma to participate in the BIO International Convention 2026 from June 22-25.
- Company will conduct partnering meetings to discuss licensing and commercialization opportunities.
- Lead drug candidate Namodenoson is in pivotal Phase III for HCC and Phase IIb for MASH.
- Piclidenoson is in pivotal Phase III for psoriasis and preparing for Phase II in Lowe Syndrome.
- Proprietary A3AR platform has demonstrated a favorable safety profile in over 1,600 patients.
- Existing regional licensing agreements have generated approximately $20 million in payments.
- Dr. Sari Fishman, VP of Business Development, will lead partnering meetings at the event.
Price Impact
More from CANF